NewLimit Raises $435 Million to Advance Longevity Research
NewLimit, a biotech startup focused on extending human healthspan by unlocking regenerative potential, has successfully secured $435 million in a Series C funding round. This substantial investment will propel the company towards human trials for its first age-reprogramming medicine.
Funding Details
The Series C round was led by Founders Fund, a prominent venture capital firm known for backing innovative technology companies. Other notable investors participating in this round include Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman, Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital.
Founders and Leadership
NewLimit was co-founded by Jacob Kimmel, Blake Byers, and Brian Armstrong, who is also known for co-founding Coinbase. Kimmel, serving as the President, has been instrumental in steering the company’s vision towards regenerative medicine and longevity research.
Use of Funds
The newly acquired funds will primarily be used to advance NewLimit's age-reprogramming medicine into human trials. This marks a significant step forward in the company's mission to extend the human healthspan. The company aims to explore the regenerative potential of its innovative treatments, focusing on reversing age-related cellular decline.
Moving Forward
With this latest injection of capital, NewLimit is positioned to make substantial progress in the field of longevity research. The company’s focus on regenerative medicine aligns with a growing interest in healthspan extension, promising potential breakthroughs in how age-related diseases and conditions are treated.
As NewLimit continues to develop its pioneering therapies, the support from a robust lineup of investors underscores confidence in the company's approach and future prospects in the biotech industry.